Loading
A Lahore trial testing whether splitting two chemotherapy drugs into smaller doses over two days works as well for lymphoma that has come back, with less harm to the kidneys and without a hospital stay.
Randomised phase 3 trial at Mayo Hospital, Lahore, sponsored by King Edward Medical University (principal investigator Abbas Khokhar). 74 adults with relapsed or refractory diffuse large B-cell lymphoma are randomised 1:1 to modified DHAP (dexamethasone 40 mg days 1 to 4, cisplatin 50 mg/m2 over 6 hours days 1 and 2, cytarabine 2 g/m2 over 3 hours days 1 and 2) or standard DHAP (dexamethasone 40 mg days 1 to 4, cisplatin 100 mg/m2 by 24-hour infusion day 1, cytarabine 2 x 2 g/m2 day 2). The primary endpoint is overall response rate by RECIL 2017; secondary endpoints are progression-free survival, toxicity by CTCAE and quality of life by EORTC QLQ-C30. Primary completion is estimated for 20 May 2027. No results are posted.
Shares Dexamethasone, Cisplatin, Diffuse large B-cell lymphoma.
Shares Dexamethasone, Cisplatin.
Shares Dexamethasone, Cisplatin.
Shares Cytarabine, Dexamethasone.
Shares Cytarabine, Diffuse large B-cell lymphoma.
Shares Cytarabine, Dexamethasone.
Shares Cytarabine, Dexamethasone, Cisplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/